CMMB · Chemomab Therapeutics Ltd ADR
United States · RS rating 11 · As of 2026-10-14
| Price | 1.29 USD |
|---|---|
| 1-day change | +4.0% |
| RS rating (overall / 1M / 3M / 12M) | 11 / 3 / 24 / 11 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 26 / 17 / 39 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +25.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +62.6% |
| Market cap (USD) | $11.7M |